Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$80.60 USD

80.60
969,063

+1.93 (2.45%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $80.59 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?

by Zacks Equity Research

Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.

Can Patient Wins Aid GW Pharmaceuticals (GWPH) Q2 Earnings?

by Zacks Equity Research

GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.

Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival?

by Zacks Equity Research

Bruker (BRKR) expects BioSpin to bode well for better organic growth in Q2.

CBM or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CBM vs. TECH: Which Stock Is the Better Value Option?

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Why the Earnings Surprise Streak Could Continue for Techne (TECH)

by Zacks Equity Research

Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sweta Killa headshot

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Sweta Killa

Sector ETF report for PBE

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

Myriad Genetics Announces Study Results Of myRisk Cancer Test

by Zacks Equity Research

The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

Zachary Stutler headshot

5 Biotech Stocks to Buy Right Now

by Zachary Stutler

here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.

CBM vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

CBM vs. TECH: Which Stock Is the Better Value Option?

Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

Bio-Techne (TECH) sees increase in revenues across key segments.

Techne (TECH) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 6.00% and 2.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANIK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ANIK vs. TECH: Which Stock Is the Better Value Option?

New Strong Sell Stocks for November 20th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Techne (TECH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 1.03% and 0.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q1 Earnings Preview: How Are Events Shaping Up?

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Techne Partners Micropoint Bioscience, Expands in China

by Zacks Equity Research

Bio-Techne (TECH) believes that its Chinese collaboration is a strategic fit as it will solidify the integration of microfluidic technology for more apt POC diagnostic tools for precision medicine.

New Strong Sell Stocks for October 3rd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)

    by Zacks Equity Research

    Momentum stock investors will love Bio-Techne (TECH) seeing its favorable price performance both in short and long term.

      The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

        Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

        by Zacks Equity Research

        Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.

          Tirthankar Chakraborty headshot

          Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

          by Tirthankar Chakraborty

          More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.